GALT Key Statistics, Chart & Performance
The current stock price of GALT is 4.03 USD. In the past month the price decreased by -29.42%. In the past year, price increased by 250.44%.
GALT Latest News, Press Relases and Analysis
GALT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.33 | 406.30B | ||
| AMGN | AMGEN INC | 15.27 | 179.83B | ||
| GILD | GILEAD SCIENCES INC | 15.34 | 155.92B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.67 | 117.47B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.41 | 82.37B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 785.67 | 52.94B | ||
| INSM | INSMED INC | N/A | 37.84B | ||
| NTRA | NATERA INC | N/A | 32.51B | ||
| BIIB | BIOGEN INC | 10.53 | 25.87B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.5 | 22.16B | ||
| INCY | INCYTE CORP | 15.64 | 19.72B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.27B |
Related stock screener links
About GALT
Company Profile
Galectin Therapeutics, Inc. is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. The company is headquartered in Norcross, Georgia and currently employs 15 full-time employees. The company went IPO on 2002-09-04. The Company’s drug candidates are based on its method of targeting galectin proteins, which are key mediators of biologic and pathologic functions. The Company’s lead drug, belapectin, is a carbohydrate-based drug that inhibits the galectin-3 protein, which is directly involved in multiple inflammatory, fibrotic, and malignant diseases for which it has Fast Track designation by the U.S. Food and Drug Administration. The lead development program is in metabolic dysfunction-associated steatohepatitis (MASH, formerly known as nonalcoholic steatohepatitis, or NASH) with cirrhosis, the most advanced form of MASH-related fibrosis. The firm's additional development programs are in the treatment of combination immunotherapy for advanced head and neck cancers and other malignancies.
Company Info
GALECTIN THERAPEUTICS INC
Suite 240, 4960 Peachtree Industrial Boulevard
Norcross GEORGIA 30071 US
CEO: Joel Lewis
Employees: 15
Phone: 16786203186
GALECTIN THERAPEUTICS INC / GALT FAQ
What does GALT do?
Galectin Therapeutics, Inc. is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. The company is headquartered in Norcross, Georgia and currently employs 15 full-time employees. The company went IPO on 2002-09-04. The Company’s drug candidates are based on its method of targeting galectin proteins, which are key mediators of biologic and pathologic functions. The Company’s lead drug, belapectin, is a carbohydrate-based drug that inhibits the galectin-3 protein, which is directly involved in multiple inflammatory, fibrotic, and malignant diseases for which it has Fast Track designation by the U.S. Food and Drug Administration. The lead development program is in metabolic dysfunction-associated steatohepatitis (MASH, formerly known as nonalcoholic steatohepatitis, or NASH) with cirrhosis, the most advanced form of MASH-related fibrosis. The firm's additional development programs are in the treatment of combination immunotherapy for advanced head and neck cancers and other malignancies.
Can you provide the latest stock price for GALECTIN THERAPEUTICS INC?
The current stock price of GALT is 4.03 USD. The price increased by 1% in the last trading session.
What is the dividend status of GALECTIN THERAPEUTICS INC?
GALT does not pay a dividend.
What is the ChartMill rating of GALECTIN THERAPEUTICS INC stock?
GALT has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
Can you provide the PE ratio for GALT stock?
GALECTIN THERAPEUTICS INC (GALT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.59).
What is the employee count for GALT stock?
GALECTIN THERAPEUTICS INC (GALT) currently has 15 employees.
Can you provide the ownership details for GALT stock?
You can find the ownership structure of GALECTIN THERAPEUTICS INC (GALT) on the Ownership tab.
GALT Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to GALT. When comparing the yearly performance of all stocks, GALT is one of the better performing stocks in the market, outperforming 97.93% of all stocks.
GALT Financial Highlights
Over the last trailing twelve months GALT reported a non-GAAP Earnings per Share(EPS) of -0.59. The EPS increased by 19.18% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -291.04% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
GALT Forecast & Estimates
7 analysts have analysed GALT and the average price target is 11.22 USD. This implies a price increase of 178.41% is expected in the next year compared to the current price of 4.03.